Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten Boers

Showing results (241-250 of 308) with videos related to

Pageof 31
Sort By:
Annals of the Rheumatic Diseases|December 2, 2016
The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remissionLilian H D van Tuyl, Martina Sadlonova, Sarah Hewlett, et al.
The Journal of Rheumatology|December 7, 2005
Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7Peter A Merkel, Philip Seo, Peter Aries, et al.
Seminars in Arthritis and Rheumatism|April 25, 2026
Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT studyDorthe B Berthelsen, Tobias Haugegaard, Mohammed M Kamso, et al.
The Journal of Rheumatology|May 3, 2019
Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology TrialsLouise Klokker, Dorthe B Berthelsen, Thasia Woodworth, et al.
Annals of the Rheumatic Diseases|August 4, 2023
Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trialAbdullah Ali Hadi Almayali, Maarten Boers, Linda Hartman, et al.
The Journal of Rheumatology|September 10, 2009
How to ascertain drug safety in the context of benefit. Controversies and concernsLee S Simon, C Vibeke Strand, Maarten Boers, et al.
The Journal of Rheumatology|March 9, 2007
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schemaMarissa N Lassere, Kent R Johnson, Maarten Boers, et al.
Annals of the Rheumatic Diseases|May 16, 2014
Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatologyMaya H Buch, Lucia Silva-Fernandez, Loreto Carmona, et al.
Annals of the Rheumatic Diseases|May 31, 2022
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trialMaarten Boers, Linda Hartman, Daniela Opris-Belinski, et al.
Seminars in Arthritis and Rheumatism|January 23, 2021
Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working groupDorthe B Berthelsen, Thasia G Woodworth, Niti Goel, et al.
Pageof 31

Showing results (241-250 of 308) with videos related to

Sort By:
Pageof 31
Annals of the Rheumatic Diseases|December 2, 2016
The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remissionLilian H D van Tuyl, Martina Sadlonova, Sarah Hewlett, et al.
The Journal of Rheumatology|December 7, 2005
Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7Peter A Merkel, Philip Seo, Peter Aries, et al.
Seminars in Arthritis and Rheumatism|April 25, 2026
Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT studyDorthe B Berthelsen, Tobias Haugegaard, Mohammed M Kamso, et al.
The Journal of Rheumatology|May 3, 2019
Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology TrialsLouise Klokker, Dorthe B Berthelsen, Thasia Woodworth, et al.
Annals of the Rheumatic Diseases|August 4, 2023
Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trialAbdullah Ali Hadi Almayali, Maarten Boers, Linda Hartman, et al.
The Journal of Rheumatology|September 10, 2009
How to ascertain drug safety in the context of benefit. Controversies and concernsLee S Simon, C Vibeke Strand, Maarten Boers, et al.
The Journal of Rheumatology|March 9, 2007
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schemaMarissa N Lassere, Kent R Johnson, Maarten Boers, et al.
Annals of the Rheumatic Diseases|May 16, 2014
Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatologyMaya H Buch, Lucia Silva-Fernandez, Loreto Carmona, et al.
Annals of the Rheumatic Diseases|May 31, 2022
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trialMaarten Boers, Linda Hartman, Daniela Opris-Belinski, et al.
Seminars in Arthritis and Rheumatism|January 23, 2021
Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working groupDorthe B Berthelsen, Thasia G Woodworth, Niti Goel, et al.
Pageof 31